Extended Data Fig. 8: Contribution of GAGs and lipoprotein receptors to lipoprotein uptake and tumour growth.
From: Glycosaminoglycan-driven lipoprotein uptake protects tumours from ferroptosis
a. Immunoblot of LDLR, SCARB1, and UGDH in HeLa cells transduced with the indicated sgRNAs. GAPDH included as a loading control. b, c. Fold change in the uptake of DiI-labelled LDL (b) and HDL (c) of the indicated HeLa cells relative to sgControl-transduced cells. d. Immunoblot of LRP8 in 786-O cells transduced with a sgControl or sgLRP8. ACTINB included as a loading control. e. Fold change in the uptake of DiI-LDL (left) and DiI-HDL (right) of the indicated 786-O cells relative to sgControl-transduced cells. f. Proliferation (log2 doublings, 5 days) of the indicated 786-O cells under ML162 treatment. g. Immunoblot of LDLR and SCARB1 in HeLa LDLR_KO (left) and SCARB1_KO (right) cells expressing a sgRNA-resistant LDLR, SCARB1 cDNA or empty vector. ACTINB and vinculin included as loading controls. h. Fold change in the uptake of DiI-LDL and DiI-HDL by the indicated HeLa cells relative to cells expressing an empty vector. i. Proliferation (log2 doublings, 5 days) of LDLR_KO and SCARB1_KO cells expressing the indicated cDNAs or an empty vector (grey) under the indicated concentrations of ML162. j. Representative images of tumours resulting from implantation of HeLa UGDH-KO, LDLR_KO, or SCARB1_KO cells expressing the indicated cDNAs or empty vector. k. Fold change in tumour weight relative to isogenic KO tumours for HeLa UGDH_KO, LDLR_KO, or SCARB1_KO cells expressing the indicated cDNAs or empty vector. b, c, e, f, h, i: Bars represent mean ± s.d.; k: Boxes represent median, first and third quartiles, and whiskers are range; b, c, e, f, h, i: n = 3 biological replicates; k: n = 10 biological replicates. Statistics by two-sided unpaired t-tests compared to sgControl-expressing cells (b, c, e, f) or empty vector transduced cells (h, i, k). For gel source data, see Supplementary Fig. 1.
